Abstract
Purpose :
To evaluate change in intraocular pressure (IOP) after micropulse laser trabeculoplasty (MLT).
Methods :
A retrospective cohort study was conducted at an ophthalmology clinic at a public hospital in New York. 71 eyes with open-angle glaucoma and no history of incisional surgery treated with MLT were followed. An Iridex IQ 532 laser with MicroPulse technology at 532 nm was used to treat 360° of the trabecular meshwork. Follow-up IOP measurements were obtained at two years. Number of topical glaucoma medications before and after MLT were recorded. Paired t-tests compared baseline to follow-up.
Results :
Significant IOP reduction occurred at 2-year follow-up (p=0.001) from pre- (M=18.19, SD=4.30) to post-MLT (M=15.86, SD=3.65). Stratifying by baseline IOP showed significant IOP reduction for IOP>19,(<p=0.001): pre- (M=22.39, SD=2.99), post-MLT (M=17.29, SD=4.09). No significant change occurred for baseline IOP<19 (p=0.44). No significant change of number of medications occurred (p=0.57).
Conclusions :
MLT appears to be a long-lasting beneficial adjunct therapy in patients with uncontrolled IOP on topical medications. Prospective randomized controlled studies would further document the utility of this treatment modality.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.